

Article

The Use of Ureates as Activators for Samarium Diiodide

Chriss E. McDonald, Jeremy D. Ramsey, Christopher C. McAtee,
Joseph Randall Mauck, Erin M Hale, and Justin A Cumens

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.6b00733 • Publication Date (Web): 20 Jun 2016

Downloaded from <http://pubs.acs.org> on June 20, 2016

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications


The Journal of Organic Chemistry is published by the American Chemical Society.
1155 Sixteenth Street N.W., Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.

The Use of Ureates as Activators for Samarium Diiodide

Chriss E. McDonald*, Jeremy D. Ramsey, Christopher C. McAtee[†], Joseph R. Mauck^{††}, Erin M. Hale, and Justin A. Cumens

Department of Chemistry, Lycoming College, 700 College Place, Williamsport, PA 17701,
United States

Email address for Chriss E. McDonald: mcdonald@lycoming.edu



ABSTRACT: A novel mode of SmI_2 activation has been developed using ureates as reaction promoters. Several ureates formed by treatment of the corresponding ureas with $n\text{-BuLi}$ have been shown to activate SmI_2 to a substantial extent towards the reduction of 1-chlorodecane. Complexes formed from SmI_2 and various ureates have been shown to be useful for the reduction of a variety of organohalides, including substrates of low reactivity such as aryl fluorides. Due to its ease of synthesis and low molecular weight, the conjugate base of triethylurea (TEU^-) was of primary focus. Visible spectroscopy and reactivity data are consistent with the hypothesis that the same complex is being formed when SmI_2 is combined with either two or four equivalents of TEU^- , in spite of the greater reactivity of $\text{SmI}_2/4 \text{ TEU}^-$ with some alkyl halides. We propose that the active reductant is an N,O chelate formed between SmI_2 and two equivalents of TEU^- .

INTRODUCTION

Samarium diiodide (SmI_2) continues to be one of the most important reagents for radical reduction in organic chemistry. A variety of organic functionalities are amenable to SmI_2 -mediated reduction through complementary one and two-electron processes.¹ However, for substrates which are reluctant toward radical reduction with SmI_2 , additives can be employed to facilitate the reaction. The most common and historically important additive is hexamethylphosphoramide (HMPA, **1**, Figure 1), which was originally reported by Inanaga to decrease overall reaction times while substantially increasing the yields for the reduction of alkyl halides.² It has been established that HMPA primarily exerts its effect by coordinating to SmI_2 to form the THF-soluble complex $[\text{SmI}_2(\text{HMPA})_4(\text{THF})_2]^{2+}2\text{I}^-$.^{3,4} This complex has proven so useful that the majority of samarium diiodide chemistry has been performed with HMPA as a cosolvent.⁵ The primary drawback of this reduction system is the deleterious health effects associated with HMPA. HMPA has been shown to be mutagenic,⁶ carcinogenic,^{7,8} and antispermatogenic.⁹ The polyhydroxylation of HMPA by cytochrome P450 oxidases is thought to be responsible for these undesirable health effects.¹⁰ Furthermore, the use of HMPA has been banned in many laboratories.^{11,12}

Chemists have expended a great deal of effort to develop alternative activators for SmI_2 -mediated reactions. Transition metal salts, most importantly NiI_2 , have proven useful for the facilitation of several reductive transformations involving alkyl halides,¹³ imines,¹⁴ anomeric pyridylsulfones,¹⁵ acid chlorides,¹⁶ and iminium triflates.^{17,18} Recent mechanistic investigations by Flowers indicate that transmetallation of alkylsamarium to alkylnickel species is primarily responsible for the enhancement of reduction in the case of alkyl halide precursors.¹⁹

Curran first reported the ability of water to enhance the reactivity of SmI_2 in THF.²⁰ The reduction of alkyl iodides, ketones, and sulfoxides proceeded more rapidly and in higher yield in the presence of H_2O . Subsequent work has explored the scope of substrates susceptible to reduction by $\text{SmI}_2/\text{H}_2\text{O}$.²¹ Aromatic carboxylic acid derivatives²² and *N*-acyl oxazolidines²³ can be reduced with SmI_2 in the presence of H_2O . These functionalities are resistant to reduction by SmI_2 in the absence of H_2O . Furthermore, Procter has employed $\text{SmI}_2/\text{H}_2\text{O}$ for the chemoselective reduction of δ -lactones,²⁴ cyclic 1,3-diester,²⁵ and barbituric acids.²⁶ High concentrations of H_2O is thought to lead to a dimeric Sm(II) aquo complex which functions as the initial electron donor in these reactions.^{27,28}




Addition of triethylamine or pyrrolidine to the $\text{SmI}_2/\text{H}_2\text{O}$ reduction system results in a further enhancement of reactivity. Synthetically useful reductions of alkyl halides,²⁹ conjugated alkenes and alkynes,³⁰ α,β -unsaturated esters,³¹ unactivated esters,³² carboxylic acids,³³ and amides³⁴ are known. The inclusion of the amine to the $\text{SmI}_2/\text{H}_2\text{O}$ reaction mixture is thought to further enhance the reactivity of the reductant by removing a proton from a water molecule complexed to the Sm(III) species formed after the initial electron transfer to substrate.³⁵

Electron rich compounds such as 1,1,3,3-tetramethylguanidine (TMG),³⁶ 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU),³⁶ and 1,3-dimethyl-2-imidazolidinone (DMI)³⁷ have also been examined as possible SmI_2 activators and have some limited applications. The conjugate base of hexamethyldisilazine has proven to be extraordinarily effective for the activation of SmI_2 towards the reduction of alkyl and aryl fluorides.³⁸ The cosolvent *N,N'*-dimethylpropyleneurea (DMPU) has been successfully used in several instances as a surrogate for HMPA.³⁹ Although less effective than HMPA, DMPU is thought to activate SmI_2 in a similar manner, by

1
2
3 coordination of its oxygen to Sm(II) resulting in an increase of electron density at the metal
4
5 center.⁴⁰
6
7

8
9 Over the past several years, we have been engaged in a program to develop
10
11 phosphoramidate-based alternative activators for SmI₂ (Figure 1A). The dimer of HMPA,
12
13 diHMPA (**2**), has proven to be approximately 1/3 as reactive as HMPA in most applications.⁴¹
14
15 Tripyrrolidine phosphoric acid triamide (TPPA, **3**) was shown to be a substantially better
16
17 activator of SmI₂ than HMPA in the reduction of alkyl halides and ketones.⁴² The enhanced
18
19 reactivity of this reducing system is attributed to both the increased basicity and the steric
20
21 compactness of the pyrrolidino moiety in TPPA relative to the dimethylamino moiety in
22
23 HMPA.^{43,44} Reissig and coworkers have shown that SmI₂/TPPA is often superior to SmI₂/HMPA
24
25 for the reductive dearomatization of γ -aryl ketones.¹² Recently, we have shown that the
26
27 conjugate base of the phosphoramidate, dipyrrolidinomethylaminophosphoric acid triamide
28
29 (DPMPA, **4**), is an extremely efficient activator of SmI₂ (Figure 1B).⁴⁵ Complexes formed from
30
31 four equivalents of the anion derived from the deprotonation of DPMPA (**5**) and SmI₂ proved to
32
33 be at least 100 times more reactive than the analogous SmI₂/HMPA complex as determined by
34
35 the reduction of 1-chlorodecane. It is presumed that DPMPA⁻ can deliver even greater electron
36
37 density to the metal center of SmI₂ thus enhancing the reductive ability of the resultant species.
38
39
40
41
42
43
44

45
46 Herein we report the extension of these efforts to the design of a series of ureates for the
47
48 activation of SmI₂ as shown in Figure 1C. We envision the synthesis of compounds where the
49
50 urea functionality is either acyclic/exocyclic (**6**) or endocyclic (**7**). A variety of advantages that
51
52 ureates might exhibit relative to phosphoramidates and phosphoramidates can be enumerated.
53
54
55
56
57
58
59
60

A reported phosphoramides for SmI_2 activation**B** previous work: phosphoramidates for SmI_2 activation**C** this work: ureates as SmI_2 activators**Figure 1.** Activators of SmI_2 .

Because of the lower valency of the functional group's central atom, ureates will have a lower molecular weight relative to DPMPA⁻. It is also reasonable to assume that upon ureate ligation to Sm(II) the resultant complex would be less sterically encumbered, which might facilitate both inner- and outer-sphere reductive processes. Furthermore, unlike HMPA and DPMPA, the urea proligands will not possess *N*-methylphosphoramidate moieties, which are known to produce mutagenic metabolites upon hydroxylation by cytochrome P450 oxidases.¹⁰

Although ureate complexes of Sm(II) have not been reported, several transition metal and lanthanide metal cations do complex with ureates to form unique organometallic species.

Ureates have been shown to coordinate with Ti(IV),⁴⁶ Fe(III),⁴⁷ Zr(IV),⁴⁸ Pd(II),⁴⁹ Hf(IV),⁵⁰ W(VI),⁵¹ and U(IV).⁵² The Zr(IV) ureates are known to catalyze hydroamination reactions,⁵³ while the Pd(II) ureates are efficient catalysts for the Heck reaction of aryl bromides.⁴⁹

RESULTS AND DISCUSSION

We began our investigation with the development of a general strategy towards the synthesis of the urea prolignands which utilized inexpensive starting material, afforded a single product, and was amenable to scale-up. Our approach to the synthesis of a group of deprotonatable acyclic/exocyclic ureas is shown in Table 1. The appropriate *N,N*-dialkylcarbamoyl chloride was treated with an excess of primary amine salt and triethylamine in CH₂Cl₂ at room temperature.⁵⁴ After filtration, an extractive workup was performed. Bulb to bulb distillation afforded the typically crystalline products in good to excellent yield (entries 1-6).

Table 1. Synthesis of Acyclic/Exocyclic Ureas.

entry	R ¹	R ²	R ³	product	yield (%)
1	Et	Et	Me	6a	76
2	Et	Et	Et	6b	84
3	Et	Et	<i>i</i> -Pr	6c	68
4	Et	Et	<i>t</i> -Bu	6d	91
5	<i>i</i> -Pr	<i>i</i> -Pr	Et	6e	98
6	-(CH ₂) ₄ -		Et	6f	74

A single step synthesis of endocyclic deprotonatable ureas was also developed (Table 2). In each case an unsymmetrical diamine in CH_2Cl_2 was treated with 1,1'-carbonyldiimidazole (CDI).⁵⁵ After an aqueous workup with an acidic wash to remove the imidazole byproduct, good yields of the resultant ureas were obtained. It was determined that this approach was not practicable for the synthesis of ureas of less than six carbons due to the inability to efficiently separate the target compound from imidazole.

Table 2. Synthesis of Endocyclic Ureas.

entry	R	n	product	yield (%)
1	<i>n</i> -Bu	1	7a	69
2	<i>n</i> -Pr	2	7b	71
3	<i>i</i> -Pr	2	7c	67

Deprotonatable ureas of lesser substitution which were used in this study and are commercially available (Figure 2) include acyclic ethylurea (**6g**), endocyclic 2-imidazolidinone (**7d**), and endocyclic propyleneurea (**7e**).




Figure 2. Commercially available deprotonatable ureas.

The reduction of 1-chlorodecane was chosen as a screening reaction to provide an initial assessment of the ability of each ureate to activate SmI_2 . Ureates were formed *in situ* following

n-BuLi addition to a solution of urea in THF (Table 3). In many cases (entries 1, 2, 7, 14, and 15) the formation of the ureate was evidenced by the development of a gel-like precipitate. The other ureates were THF-soluble. It was considered prudent to exclude a proton source from the reaction mixture because of the likely partial reprotonation of the ureates to the neutral urea. This would make assessment of the extent of activation difficult. Addition of the deep blue solution of SmI₂ in THF to the ureate resulted in the formation of a brown soluble complex in each case.

Table 3. Relative Reactivity of SmI₂ and Additive with 1-Chlorodecane

$$\text{H}_3\text{C}(\text{CH}_2)_9\text{Cl} \xrightarrow[\text{time, 0}^\circ\text{C}]{\text{SmI}_2 (3.0 \text{ eq}), (0.05 \text{ M in THF})} \text{H}_3\text{C}(\text{CH}_2)_9\text{H}$$

additive (12.0 eq), *n*-BuLi (12.0 eq)

entry ^a	additive	yield (%) at 1 min ^b	yield (%) at 1 h ^b
1	6a	9	28
2	6b	16	32
3	6c	15	43
4	6d	0	0
5	6e	36	66
6	6f	5	28
7	6g	<1	<1
8	6b^c	<1	<1
9	6b^d	0	0
10	6b^e	<1	1
11	7a	11	55
12	7b	43	77
13	7c	26	43
14	7d	10	13
15	7e	5	14
16	1^c	<1	<1
17	3^c	<1	<1
18	4	90	99
19	H ₂ O/ pyrrolidine ^c	10	22
20	H ₂ O/ pyrrolidine ^{c,f}	11	31

^a1-Chlorodecane added last over 2 s. ^bYield determined by GC with tetradecane as internal standard. ^c*n*-Bu-Li not used.

^dSmI₂ not used. ^eDeprotonation with NaH/DMF. ^fH₂O added last

This color change is consistent with the complex formed between SmI_2 and DPMPA.⁴⁵ In screening studies of this sort, SmI_2 has typically been quenched with 0.1 M I_2 in hexane.^{42,45,56,57} Because of the absence of a proton source in these reaction mixtures, a mixture of decane and 1-iododecane is formed upon quenching with I_2 in hexane as determined by GC-MS. Therefore we used an open-air 0.1 M solution of *t*-BuOH in hexanes as the quench method in order to avoid the 1-iododecane side product. Thus, one minute after the sequential addition of tetradecane (internal standard) and 1-chlorodecane were added to the SmI_2 /ureate mixture, an aliquot was removed and quenched with *t*-BuOH in hexanes. A second aliquot was removed at 1 hour. This order of addition, with 1-chlorodecane being added to a mixture of SmI_2 and ureate, is one of several possible orders of addition. A second order of addition will also be explored (*vide infra*).

Most of the ureates exhibited an ability to activate SmI_2 for the reduction of 1-chlorodecane. Acyclic ureas **6a-6c** which possess an increasing degree of substitution on the deprotonatable nitrogen, activate SmI_2 to a similar extent (entries 1-3). Like **6a-6c**, the *t*-butyl congener **6d** forms a brown complex with SmI_2 , but no reduction of 1-chlorodecane was observed (entry 4). Diisopropylethylurea (**6e**) proved to be somewhat more efficient at the activation of SmI_2 relative to **6a-c** (entry 5). Pyrrolidino-substituted urea **6f** was similar to **6a-c** in its ability to activate SmI_2 (entry 6). Ethylurea (**6f**) was not an effective activator of SmI_2 (entry 7). Entry 8 demonstrates that urea deprotonation is critical to reaction success. The neutral version of **6b**, triethylurea (TEU), forms a violet complex with SmI_2 , but only traces of decane was observed under these mild reaction conditions. The necessity of SmI_2 in the reaction mixture is illustrated in entry 9. In the absence of SmI_2 no decane is produced. As has been shown previously, the presence of 12 equivalents of LiBr in the reaction mixture does not sufficiently activate SmI_2 to allow for the reduction of 1-chlorodecane under these mild reaction

conditions.⁴⁵ To further examine the potential role of Li^+ in this reduction system, the anion of **7b** was produced with NaH. This reaction was surprisingly sluggish. Success was achieved by heating TEU and NaH with DMF at 100 °C, cooling to rt, then removal of the DMF in vacuo. Addition of THF and SmI_2 afforded a dark brown suspension. This mixture afforded only small amounts of decane (entry 10).

The ureates derived from endocyclic ureas **7a-c** proved to be excellent activators of SmI_2 . The ureate of *N*-propyl propyleneurea (**7b**, PPU^- , entry 12) was shown to be an especially good activator, the best of the ureates, although DPMPA^- (entry 18) is substantially better. The anions derived from the two endocyclic commercially available ureas (**7d** and **7e**) were shown to be modest activators of SmI_2 (entries 14 and 15).

As expected the neutral phosphoramides HMPA (entry 16) and TPPA (entry 17) afforded only trace amounts of decane under these conditions. On the other hand, the $\text{SmI}_2/\text{H}_2\text{O}$ /pyrrolidine reagent system is capable of reducing 1-chlorodecane under these conditions (0.05 M SmI_2 at 0 °C). Using a protocol that most closely matches those described for the ureates in Table 3 with 1-chlorodecane being added last, yields of 10 and 22% were afforded at the one minute and one hour mark respectively (entry 19). When the order of addition was modified to match those typically used for this reagent system (H_2O added last) the yields increased (entry 20).⁵⁸


Based on this initial screening three ureas were selected for further study. Triethylurea, TEU (**6b**), was selected for its ease of synthesis in multi-gram quantities, relatively low molecular weight, and its extended shelf life without discoloration. Its lack of *N*-methyl groups is also a desirable structural feature.^{10,12} The endocyclic ureas *N*-butylimidazolidinone (BI, **7a**)

1
2
3 and *N*-propyl propyleneurea (PPU, **7b**) were selected for their low molecular weight and greater
4
5 degree of SmI₂ activation. It should be noted that PPU, the best urea activator found in this
6
7 study, has a pair of undesirable properties. It is a low melting solid, which makes it difficult to
8
9 manipulate. Furthermore it is not bench stable which is evident by its discoloration after a few
10
11 days storage at room temperature.
12
13

14
15 Because of the centrality of triethylurea to our program, the next task was to further
16
17 explore the reduction of 1-chlorodecane with SmI₂/TEU⁻. Previous work has shown that the
18
19 order of addition can be a significant factor in the success of SmI₂-mediated reactions.^{45,59} The
20
21 results in Table 3 were generated by the addition of 1-chlorodecane to a mixture of SmI₂ and
22
23 TEU⁻. This order of addition corresponds to method A in Table 4. The addition of SmI₂ to a
24
25 mixture of TEU⁻ and 1-chlorodecane corresponds to method B. It is readily apparent that the
26
27 order of addition is a significant factor in this reduction as well. Adding SmI₂ last (entry 2,
28
29 method B) leads to a substantial increase in yield of the product decane relative to the addition of
30
31 1-chlorodecane last (entry 1, method A). It is unclear why the order of addition has such a
32
33 dramatic effect on the efficiency of the reduction. The effect of changing the ratio of TEU⁻ to
34
35 SmI₂ using method B was also explored. Interestingly, even when a single equivalent of TEU⁻ is
36
37 present relative to SmI₂, the resultant blue-black solution is capable of reduction and a 21% yield
38
39 of decane was obtained at the 1 hour mark (entry 3). As expected the yield of decane increased
40
41 as the proportion of TEU⁻ ligand was increased relative to SmI₂ (entries 2-5). Inclusion of a
42
43 proton source and its effect on reaction efficacy was examined in entries 6-8. With the addition
44
45 of *tert*-amyl alcohol (*t*-AmOH) there was an observed overall increase in the yield of decane
46
47 (entry 6). *t*-AmOH was chosen as the proton source rather than the more typical *t*-BuOH
48
49 because it is a liquid at rt, which simplifies the procedure. In the presence of this proton source
50
51
52
53
54
55
56
57
58
59
60

even the 1:2 complex afforded a near quantitative yield of decane at the one hour mark with method B (entry 7). The addition of *t*-AmOH facilitated method A as well (entry 8).

Table 4. Optimization of the Reduction of 1-Chlorodecane with SmI₂/TEU⁻.



entry	TEU (eq)	<i>n</i> -BuLi (eq)	<i>t</i> -AmOH (2.0 eq)	method ^a	yield (%) at 1 h ^b
1	12	12	no	A	32
2	12	12	no	B	85
3	3	3	no	B	21
4	6	6	no	B	66
5	9	9	no	B	76
6	12	12	yes	B	99
7	6	6	yes	B	92
8	6	6	yes	A	60











^aMethod A: 1-chlorodecane added last over 2 s. Method B: SmI₂ added last over 30 s.

^bYield determined by GC with tetradecane as internal standard.

The first synthetic application of SmI₂/ureate complexes to be explored is the reduction of alkyl and aryl halides. We began by focusing our efforts on the “low ratio” SmI₂/ 2 TEU/2 *t*-AmOH combination that was shown to be so effective in the optimization study described in Table 4 as well as the “high ratio” 1:4 complexes formed with the ureates TEU⁻, BI⁻ and PPU⁻. Results for reductions of various alkyl halides with SmI₂/ 2 TEU/2 *t*-AmOH are shown in Table 5. Typically these reactions are started at 0 °C and allowed to warm to room temperature overnight. Bromides are smoothly reduced as shown in entries 1 and 2. Because of the presence of the amide functional group in substrate **8b**, this reaction was started at -84 °C, and allowed to warm slowly to room temperature (entry 2). The survival of the amide functionality is noteworthy given that Procter has shown that the highly reactive reducing system SmI₂/H₂O/Et₃N converts amides to the corresponding reduced alcohols.³⁴ Reduction of alkyl

1
2
3 chlorides proceeded smoothly and afforded a single product in good to excellent yield (entries 3-
4
5 5). These reaction conditions are substantially milder than what is required for the reduction of
6
7 primary alkyl chlorides by $\text{SmI}_2/4$ HMPA (8 h at 60 °C).² Aryl chloride **8f** was cleanly reduced
8
9 as well, once again with survival of the amide functional group (entry 6). Electron rich aryl
10
11 chlorides **8g** and **8h** proved more difficult to reduce. These reactions did not proceed to
12
13 completion with the $\text{SmI}_2/2$ TEU/ 2 *t*-AmOH combination, even when additional reductant was
14
15 provided (entries 7-10). The reduction of pyridyl fluoride **8i** proceeded to completion and was
16
17 isolated in good yield (entry 11). Aryl fluoride **8j** was not reduced under these conditions (entry
18
19 12).
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60









Table 5. The Reduction of R-X with $\text{SmI}_2/2 \text{ TEU}^-$.^a

		$\text{R-X} \xrightarrow[\text{TEU (6.6 eq), } n\text{-BuLi (6.6 eq)}]{\text{SmI}_2 \text{ (3.3 eq), (0.07 M in THF)}} \text{R-H}$			
		8		9	
entry ^a		R-X (8)	% conversion ^b	% yield (9)	
1	8a		100	91	
2 ^c	8b		100	94	
3	8c		100	80	
4	8d		100	87	
5	8e		100	74	
6 ^c	8f		100	74	
7	8g		71	45	
8 ^d			79	57	
9	8h		24	11	
10 ^d			44	27	
11	8i		100	73	
12	8j		0	0	

^a SmI_2 added last over 30 s at 0°C. ^bConversions were measured by ^1H NMR integration calculated as a ratio of product to starting material. ^cPerformed at -84°C to rt. ^d5.0 eq SmI_2 , 10.0 eq TEU, and 10.0 eq $n\text{-BuLi}$.

As was illustrated in Table 4, it is known that increasing the proportion of ureate in the reaction vessel enhances the reductive power of the mixture. We therefore performed a series of reductions with $\text{SmI}_2/4 \text{ TEU}^-$ as well as the more reactive $\text{SmI}_2/4 \text{ BI}^-$, and $\text{SmI}_2/4 \text{ PPU}^-$. As expected reduction of alkyl chlorides worked well with $\text{SmI}_2/4 \text{ TEU}^-$ (Table 6, entries 1, 3, and 4). The importance of using the correct order of addition can once again be seen in entry 2. When cholesteryl chloride (**8c**) is added to $\text{SmI}_2/4 \text{ TEU}^-$, large amounts of starting material remain in the decolorized reaction mixture upon workup. Chloroaryl ether **8g** was incompletely reduced by $\text{SmI}_2/4 \text{ TEU}^-$, but could be completely reduced with the more reactive $\text{SmI}_2/4 \text{ BI}^-$, and $\text{SmI}_2/4 \text{ PPU}^-$ (entries 5-7). Chloroaniline **8h** could be fully reduced only by the most reductive complex under study, $\text{SmI}_2/4 \text{ PPU}^-$ (entries 8-10). Aryl fluoride **8j** was amenable to complete reduction by $\text{SmI}_2/4 \text{ PPU}^-$ but not other $\text{SmI}_2/\text{ureate}$ complexes (entries 11 and 12). Fluoroaryl ether **8k** can also be efficiently reduced by $\text{SmI}_2/4 \text{ PPU}^-$ (entry 13). Cholesteryl fluoride was fully resistant to reduction by $\text{SmI}_2/4 \text{ PPU}^-$ with or without the addition of two equivalents of *t*-AmOH (entries 14 and 15).


Table 6. The Reduction of R-X with SmI₂/4 Ureate⁻ complexes.^a

		$\text{R-X} \xrightarrow[\text{urea (13.2 eq), } n\text{-BuLi (13.2 eq)}]{\text{SmI}_2 \text{ (3.3 eq), (0.07 M in THF)}} \text{R-H}$			
		8		9	
entry ^a	R-X (8)	urea	% conversion ^b	% yield (9)	
1	8c 	TEU	100	84	
2 ^c		TEU	52	44	
3	8d 	TEU	100	83	
4	8e 	TEU	100	79	
5 ^d	8g 	TEU	75	55	
6 ^d		BI	100	77	
7 ^d		PPU	100	87	
8 ^d	8h 	TEU	25	15	
9 ^d		BI	86	75	
10 ^d		PPU	100	83	
11 ^d	8j 	BI	0	0	
12 ^d		PPU	100	85	
13 ^d	8k 	PPU	100	74	
14	8l 	PPU	0	0	
15 ^e		PPU	0	0	

^aSmI₂ added last over 30 s at 0°C. ^bConversions were measured by ¹H NMR integration calculated as a ratio of product to starting material. ^c**8c** added last over 2 s. ^d4.0 eq SmI₂, 16.0 eq urea, and 16.0 eq *n*-BuLi. ^e2.0 eq *t*-AmOH.

Dichloride **10** was used to evaluate the ability of various SmI₂-based reagents systems to effect selective monodechlorination (Table 7). From previous work it was expected that the aryl chloride bond would be more susceptible to reduction. Reduction of **10** with three equivalents of

Table 7. Comparison of Additives in the Reduction of Dichloride **10**.^a



entry	additive (eq)	<i>n</i> -BuLi (eq)	% conversion ^b	% 11	yield (%) ^c 12	13
1	HMPA (12)	-	95	76	<1	12
2	TPPA (12)	-	96	85	<1	7
3	TEU (6)	6	92	85	<1	0
4	TEU (12)	12	100	75	<1	19
5	DPMPA (12)	12	82	52	<1	16

^aSmI₂ (0.05 M) added last over 8 min. ^bConversions were measured by ¹H NMR. Integration calculated as a ratio of product to starting material. ^cIsolated yields unless noted.

SmI₂/4 HMPA in the presence of 2 equivalents of *t*-AmOH provided a 76% yield of alkyl chloride **11**, a trace of the alternative product, aryl chloride **12**, and a 12% yield of the overreduction product **13** (entry 1). A modest improvement in selectivity was noted with SmI₂/TPPA (entry 2). Reduction with three equivalents of SmI₂/ 2 TEU⁻ in the presence of 2 equivalents of *t*-AmOH was more successful, providing almost exclusively the desired **11** (entry 3). When SmI₂/4 TEU⁻ was employed the reaction went to completion but a substantial amount of **13** was observed. The highly reactive phosphoramidate-based reagent SmI₂/4 DPMPA⁻








proved to be the least selective (entry 5). Thus the $\text{SmI}_2/2 \text{ TEU}^-$ reagent system has thus been shown to be the most selective of those evaluated for the monoreduction of dichloride **10**.

To gain insight into the nature of the species formed during the addition of SmI_2 to TEU^- , a series of alkyl halides and unsaturated hydrocarbons were subjected to reduction. This method of estimating chemical reduction potential was employed because $\text{SmI}_2/\text{TEU}^-$ complexes are not amenable to the determination of their thermodynamic reduction potential by cyclic voltammetry due to irreversible oxidation of the species in the electrochemical cell. The inability to obtain useful information about the reduction potential of very reactive SmI_2 complexes by cyclic voltammetry has been noted previously.^{29,45} As pointed out by Procter, using the reduction of hydrocarbons to estimate redox potentials often provides results that are substantially different than those obtained by cyclic voltammetry. For example SmI_2 in THF has a thermodynamic redox potential of -0.89 V (vs. SCE) as determined by cyclic voltammetry but can reduce the aromatic hydrocarbons acenaphthylene ($E_{1/2} = -1.65 \text{ V}$) and cyclooctatetraene ($E_{1/2} = -1.83 \text{ V}$).⁶⁰ In spite of the disparity in values obtained for thermodynamic redox potential by cyclic voltammetry and effective redox potential by determination of which substrates are susceptible to reduction, both methodologies have proven useful in the characterization of lanthanide complexes. It is also worthy of note that the unsaturated hydrocarbons are reduced by an outer-sphere mechanism,⁵⁸ while the outer-sphere character of the reduction of alkyl halides decreases from RBr to RCl , and presumably further still with R-F .⁴

Results for the determination of effective redox potential of both $\text{SmI}_2/2 \text{ TEU}^-$ and $\text{SmI}_2/4 \text{ TEU}^-$ are presented in Table 8. Interestingly, combinations of SmI_2 and TEU^- in both ratios behaved identically. Based on the ability of both complexes to rapidly reduce *trans*-stilbene, 1-bromodecane, naphthalene, styrene, and 1-chlorodecane, but not 1-fluorodecane or

benzene, an estimate of ca. -2.8 (vs. SCE) for the effective reducing power of both $\text{SmI}_2/2 \text{ TEU}^-$ and $\text{SmI}_2/4 \text{ TEU}^-$ can be obtained. This represents an estimated increase in effective reducing power of approximately 1.0 V relative to SmI_2 in THF. For comparison, the estimates of effective reducing power of $\text{SmI}_2/\text{H}_2\text{O}$ and $\text{SmI}_2/\text{H}_2\text{O}/\text{amine}$ are -2.2 V⁶⁰ and -2.7 V⁵⁸ vs. SCE respectively by this methodology.

Table 8. Reduction of Hydrocarbons and 1-Halodecanes with $\text{SmI}_2/\text{TEU}^-$ Complexes.

entry	substrate	$E_{1/2}(\text{V})^a$	reduction with $\text{SmI}_2/2 \text{ TEU}^-^b$	reduction with $\text{SmI}_2/4 \text{ TEU}^-^b$
1		-2.21	✓	✓
2		-2.29	✓	✓
3		-2.61	✓	✓
4		-2.65	✓	✓
5		-2.79	✓	✓
6		-2.97	✗	✗
7		-4.00	✗	✗

^aIn volts vs SCE. ^b% yield >90% using tetradecane as internal standard.

Visible spectroscopy was also employed to characterize $\text{SmI}_2/\text{TEU}^-$ complexes. The visible spectrum of SmI_2 in THF is typified by a set of three absorbance maxima around 422, 557, and 626 nm.^{4,45} The solution is deep blue in color. Upon addition of a THF solution of SmI_2 to a single equivalent of TEU^- the latter two absorption maxima broaden and shift to slightly lower maxima at 551 and 620 nm (Figure 3). This solution appears blue-black in color. The visible spectra of the 1:2, 1:3, and 1:4 complexes of SmI_2 and TEU^- , although not identical, are

strikingly similar in appearance, with a deep brown color, and *very* broad absorption maxima at 407 and 614 nm.




Figure 3. Normalized (at 500 nm) visible spectra recorded at 10 mM SmI_2 in THF.

This is congruent with our experience examining $\text{SmI}_2/\text{DPMPA}^-$ mixtures. The 1:1 mixture of SmI_2 and DPMPA^- is blue-black in color, with a broad peak at 546 nm, while the 1:2, 1:3, and 1:4 mixtures of $\text{SmI}_2/\text{DPMPA}^-$ are deep brown in color with a single broad absorbance bands centered at 405 nm.

The available evidence strongly suggest that the same complex is present whether $\text{SmI}_2/2$ TEU^- , $\text{SmI}_2/3$ TEU^- , or $\text{SmI}_2/4$ TEU^- is employed. As shown in Table 4, the dramatic increase in

the yield of decane at one hour in the reduction of 1-chlorodecane occurs when the ratio changes from 1:1 SmI₂/TEU⁻ (entry 3, 21%) to 1:2 SmI₂/TEU⁻ (entry 4, 66%). The smaller additional gains in reactivity of SmI₂/TEU⁻ with alkyl halides when greater than two equivalents of TEU⁻ are employed in the reaction mixture can be explained by the role very polar species play in the activation of carbon-halogen bonds.⁶¹ As detailed by Flowers, polar species such as HMPA coordinate to the carbon-halogen bond and activate the bond toward the initial reduction by Sm(HMPA)₄(THF)₂²⁺2I⁻.

We believe that the presence of TEU⁻ beyond the two equivalents required to saturate the metal center with ureate ligand in the reaction mixture would similarly activate carbon-halogen bonds toward electron transfer from SmI₂/2 TEU⁻. The visible spectra shown in Figure 3 are consistent with the presence of identical complexes at ratios of 1:2, 1:3, and 1:4 of SmI₂ and TEU⁻. Dramatic changes occur in the visible spectra as the proportion of TEU⁻ increases in mixtures of SmI₂/TEU⁻ until a 1:2 ratio is achieved. Changes in the visible spectra essentially cease as the proportion of TEU⁻ is changed from 1:2 to 1:4. The results for the reduction of hydrocarbons and alkyl halides by the two different reagent mixtures (Table 8) also suggests that there are two equivalents of TEU⁻ coordinated to SmI₂ in each case.

The evidence that the active reductant is a 1:2 complex of SmI₂ and TEU⁻ implies that the ligand is coordinating to the Sm(II) center as an N,O chelate. The coordination of two such ligands around the metal may preclude the incorporation of additional ureates. Indeed structurally defined bis-N,O chelates of monoureates to Ti(IV) and Zr(IV) are known.⁶²

CONCLUSION

In our preceding work we have developed a series of phosphoramidate-based HMPA surrogates (DiHMPA, TPPA, DPMPA⁻) for the activation of the important reducing agent SmI₂.

This work focused on the synthesis, evaluation, use, and characterization of ureates for the activation of SmI_2 . A series of deprotonatable ureas were screened for the ability to activate SmI_2 for the reduction of 1-chlorodecane. One acyclic urea, TEU, and two endocyclic ones, BI and PPU, were selected for further study. The $\text{SmI}_2/\text{TEU}^-$ reducing system has been found to effectively reduce alkyl and aryl halides. The “low ratio” reagent system $\text{SmI}_2/2 \text{ TEU}^-/2 t\text{-AmOH}$ is a substantially more powerful reducing agent than $\text{SmI}_2/4 \text{ HMPA}$ and is capable of reducing a range of alkyl chlorides. Selective reductions are also possible. Haloamides can be selectively dehalogenated by this reagent. The alkyl halide component of an alkylaryl dichloride can be selectively reduced more efficiently by $\text{SmI}_2/2 \text{ TEU}^-/2 t\text{-AmOH}$ than by the four other SmI_2 -based reagent systems that were evaluated. The “high ratio” complexes of SmI_2 with TEU^- , BI^- , and PPU^- are even more reactive and capable of the reduction of even more reluctant radical precursors such as electron rich aryl chlorides and fluorides. The reduction of 1-chlorodecane with various SmI_2 /ureate combinations, which was used as a screening reaction, accurately predicted the relative degree of activation of SmI_2 by TEU^- , BI^- , and PPU^- in subsequent synthetically relevant reductions.

Determination of which hydrocarbon and alkyl halide substrates are susceptible to reduction by $\text{SmI}_2/2 \text{ TEU}^-/2 t\text{-AmOH}$ and $\text{SmI}_2/4 \text{ TEU}^-/2 t\text{-AmOH}$ suggest that the same reductant may be present in both cases. Estimates of -2.8 (vs. SCE) V for both $\text{SmI}_2/2 \text{ TEU}^-/t\text{-AmOH}$ and $\text{SmI}_2/4 \text{ TEU}^-/t\text{-AmOH}$ for thermodynamic redox potentials were obtained, which indicates they are more powerful reductants than the very useful $\text{SmI}_2/\text{H}_2\text{O}$ and $\text{SmI}_2/\text{H}_2\text{O}/\text{amine}$ reagent systems. Comparison of visible spectra of various ratios of SmI_2 and TEU^- suggest that two TEU^- ligands are sufficient to saturate the metal center.

EXPERIMENTAL SECTION

General. Dichloromethane, toluene, DMF, 1-chlorodecane, *i*-Pr₂NH, benzyl bromide, Et₃N, pyridine, pyrrolidine, and HMPA were distilled from CaH₂ prior to use. Tetrahydrofuran was distilled from Na/benzophenone and sparged with argon for 15 min prior to use. Water and pyrrolidine were also sparged with argon for 15 min prior to use. All ureas, TPPA, and DPMPA were azeotropically dried with toluene in Schlenkware prior to use in SmI₂ reactions. *n*-Butyllithium was purchased as a 2.5 M solution and used as received. The concentration of SmI₂ in THF was confirmed by titration with I₂.⁶³ Glass-coated stir bars were used for all SmI₂ reactions. All reactions were performed under nitrogen or argon atmosphere in oven-dried glassware. Reagent transfer was accomplished using gas-tight syringes. NMR spectra were recorded at room temperature (300 MHz for ¹H and 75 MHz for ¹³C) in CDCl₃. Chemical shifts are reported in δ parts per million referenced to residual solvent proton resonance of CDCl₃ (7.28 ppm) or the solvent carbon resonance of CDCl₃ (77.0 ppm). Column chromatography was accomplished using silica gel (70-230 mesh) as the stationary phase and mixtures of hexanes and ethyl acetate as the mobile phase. Thin-layer chromatography was performed using silica gel plates with fluorescent indicator. Visualization was accomplished by UV light (254 nm) or iodine.

GC-MS analyses were performed using a GC system equipped with a column of fused silica (length 30 m, internal diameter 0.25 mm, film 0.25 μm of diphenyl dimethyl polysiloxane) and a EI/CI ion trap detector. He was used as the carrier gas. The injector temperature was 250 °C. The initial oven temperature was 40 °C with an initial hold time of 2 min, with a 20 °C/min ramp to a final temperature of 300 °C and then held at that temperature for 6 min. A split ratio of 10 was employed.

GC analyses were performed using a GC system equipped with a column of fused silica (length 30 m, internal diameter 0.25 mm, film 0.25 μm of diphenyl dimethyl polysiloxane) and a FID detector. He was used as the carrier gas. The injector temperature was 250 $^{\circ}\text{C}$. The initial oven temperature was 50 $^{\circ}\text{C}$ with an initial hold time of 2 min, with a 10 $^{\circ}\text{C}/\text{min}$ ramp to a final temperature of 250 $^{\circ}\text{C}$ and then held at that temperature for 10 min. A split ratio of 10 was employed.

High-resolution mass spectrometry was performed by direct insertion into the EI source. Ions were separated by a double focusing sector (magnetic and electric sectors) mass analyzer and then detected. Positive ion mode was employed.

Visible spectra were recorded at room temperature using a spectrometer coupled to an UV-vis-NIR source and a 300 μm transmission dip probe, capable of a transmission path length of 2 mm.

General Procedure for the Synthesis of 1,1-Diethyl-3-alkyl Ureas

Dichloromethane (11 mL) was added to diethylcarbamoyl chloride (2.80 mL, 0.0221 mol). The appropriate alkylamine hydrochloride (0.0663 mol) was added to the mixture. Triethylamine (9.3 mL, 0.066 mol) was added and the heterogenous mixture was allowed to stir at rt for 48 h. Water (15 mL) was added and the mixture was extracted with CHCl_3 (5 X 20 mL). The resultant extract was washed with 10% NaOH (10 mL) and water (10 mL), dried over Na_2SO_4 , and concentrated under reduced pressure. Distillation afforded the purified product.

1,1-Diethyl-3-methylurea (6a). Distillation (2 mm Hg, 128-130 $^{\circ}\text{C}$) yielded 2.18 g (76 %) of the title compound **6a** as a white solid, mp 34-35 $^{\circ}\text{C}$ (lit.⁶⁴ 34-35 $^{\circ}\text{C}$). IR (ATR) cm^{-1} 3227, 2970, 2931, 1622, 1526, 1490, 1375. ^1H NMR (300 MHz; CDCl_3 δ , ppm) 4.85-4.63 (b, 1H), 3.18 (q, *J*

= 7.1 Hz, 4H), 2.70 (d, J = 4.6 Hz, 3H), 1.03 (t, J = 7.1 Hz, 6H). ^{13}C NMR (75 MHz; CDCl_3 δ , ppm) 157.9, 40.7, 27.2, 13.6.⁶⁴

1,1-Diethyl-3-ethylurea (6b). Distillation (0.4 mm Hg, 140-145 °C) yielded 2.67 g (84 %) of the title compound **6b** as a white solid, mp 60-62 °C (lit.⁶⁵ 62 °C). IR (ATR) cm^{-1} 3443, 2972, 2931, 2871, 1614, 1529, 1491, 1272. ^1H NMR (300 MHz; CDCl_3 δ , ppm) 4.50-4.39 (b, 1H), 3.22-3.15 (m, 6H), 1.08-1.03 (m, 9H). ^{13}C NMR (75 MHz; CDCl_3 δ , ppm) 157.1, 40.8, 35.3, 15.5, 13.6.

1,1-Diethyl-3-isopropylurea (6c). Distillation (2 mm Hg, 175-178 °C) yielded 2.38 g (68 %) of the title compound **6c** as a white solid, mp 68-69 °C. IR (ATR) cm^{-1} 3359, 3332, 2972, 2929, 1611, 1530, 1491, 1224. ^1H NMR (300 MHz; CDCl_3 δ , ppm) 4.11-3.96 (b, 1H), 4.00, (hept, J = 6.3 Hz, 1H), 3.24 (q, J = 7.1 Hz, 4H), 1.16-1.11 (m, 12H). ^{13}C NMR (75 MHz; CDCl_3 δ , ppm) 156.6, 42.3, 41.0, 23.6, 13.8.⁶⁶

1,1-Diethyl-3-tert-butylurea (6d). Distillation (0.4 mm Hg, 110-115 °C) yielded 3.49 g (91 %) of the title compound **6d** as a white solid, mp 75-76 °C. IR (ATR) cm^{-1} 3333, 2967, 2929, 1621, 1528, 1489, 1357. ^1H NMR (300 MHz; CDCl_3 δ , ppm) 4.23-4.11 (b, 1H), 3.22 (q, J = 7.1 Hz, 4H), 1.35 (s, 9H), 1.12 (t, J = 7.1 Hz, 6H). ^{13}C NMR (75 MHz; CDCl_3 δ , ppm) 156.5, 50.5, 40.9, 29.6, 13.8.⁶⁶

1,1-Diisopropyl-3-ethylurea (6e). Dichloromethane (11 mL) was added to diisopropylcarbamoyl chloride (3.61 g, 0.0221 mol). Ethylamine hydrochloride (5.40 g, 0.0663 mol) was added to the mixture. Triethylamine (9.3 mL, 0.066 mol) was added and the mixture was allowed to stir at rt for 48 h. Water (15 mL) was added and the mixture was extracted with CHCl_3 (5 X 20 mL). The resultant extract was washed with 10% NaOH (10 mL) and water (10 mL), dried over Na_2SO_4 , and concentrated under reduced pressure. Distillation (0.9 mm Hg,

145-152 °C) yielded 3.74 g (98 %) of the title compound **6e** as a white solid, mp 75-77 °C. IR (ATR) cm^{-1} 3318, 2968, 2929, 1609, 1525, 1452, 1314, 1301. ^1H NMR (300 MHz; CDCl_3 δ , ppm) 4.21-4.09 (b, 1H), 3.89-3.80 (m, 2H), 3.30-3.21 (m, 2H), 1.22 (d, J = 6.9 Hz, 12H), 1.12 (t, J = 7.2 Hz, 3H). ^{13}C NMR (75 MHz; CDCl_3 δ , ppm) 157.3, 44.9, 35.3, 21.3, 15.5.⁶⁷

3'-Ethyl pyrrolidinecarboxamide (6f). Dichloromethane (5.9 mL) was added to 1-pyrrolidinecarbonyl chloride (1.30 mL, 0.0118 mol). Ethylamine hydrochloride (2.89 g, 0.0354 mol) was added to the mixture. Triethylamine (4.9 mL, 0.035 mol) was added and the mixture was allowed to stir at rt for 48 h. Water (10 mL) was added and the mixture was extracted with CHCl_3 (5 X 15 mL). The resultant extract was washed with 10% NaOH (10 mL) and water (10 mL), dried over Na_2SO_4 , and concentrated under reduced pressure. Distillation (1.3 mm Hg, 175-180 °C) yielded 1.24 g (74 %) of the title compound **6f** as a white solid, mp 83-84 °C. HRMS (EI) m/z : $[\text{M}^+]$ calcd for $\text{C}_7\text{H}_{14}\text{N}_2\text{O}$ 142.1101; found 142.1101. IR (ATR) cm^{-1} 3295, 2962, 2926, 2865, 1618, 1537, 1435, 1337. ^1H NMR (300 MHz; CDCl_3 δ , ppm) 4.99-4.79 (b, 1H), 3.00-2.96 (m, 4H), 2.89-2.85 (m, 2H), 1.54-1.49 (m, 4H), 0.76 (t, J = 7.1 Hz, 3H). ^{13}C NMR (75 MHz; CDCl_3 δ , ppm) 156.4, 44.6, 34.4, 24.7, 15.0.

General Procedure for the Synthesis of Endocyclic Ureas.

Dichloromethane (65 mL) was added to the appropriate diamine (0.0259 mol). After cooling the stirred mixture in an ice-water bath, 1,1'-carbonyldiimidazole (4.20 g, 0.0259 mol) was added in four portions over 1 h to the mixture. The mixture was allowed to warm to rt and stir for 24 h. Water (10 mL) was added and the mixture was extracted with CHCl_3 (5 X 25 mL). The resultant extract was stirred with 10% HCl (20 mL) for 30 min, then partitioned. The organic layer was

washed with 10% NaOH (10 mL) and water (10 mL), dried over Na₂SO₄, and concentrated under reduced pressure.

N-Butylethylene urea (7a). Distillation (0.5 mm Hg, 186-190 °C) yielded 2.54 g (69 %) of the title compound **7a** as a white solid, mp 39-40 °C (lit.⁶⁸ 36-39 °C). IR (ATR) cm⁻¹ 3209, 3090, 2952, 2930, 2867, 1684, 1495, 1457, 1439. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 5.36 (b, 1H), 3.41 (b, 4H), 3.16 (t, *J* = 7.2 Hz, 2H), 1.51-1.43 (m, 2H), 1.36-1.29 (m, 2H), 0.92 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 163.4, 44.9, 43.2, 38.3, 29.6, 19.9, 13.7.

N-Propylpropylene urea (7b). Distillation (1.7 mm Hg, 200-208 °C) yielded 2.61 g (71 %) of the title compound **7b** as a white solid, mp 39-40 °C. HRMS (EI) *m/z*: [M⁺] calcd for C₇H₁₄N₂O 142.1101; found 142.1102. IR (ATR) cm⁻¹ 3232, 2960, 2933, 2872, 1637, 1516, 1454, 1305. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 6.96-5.98 (b, 1H), 3.34-3.23 (b, 6H), 1.97-1.89 (m, 2H), 1.61-1.48 (m, 2H), 0.87 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 156.6, 49.4, 45.2, 39.9, 21.4, 20.6, 11.0.

N-isoPropylpropylene urea (7c). Distillation (0.9 mm Hg, 199-202 °C) yielded 2.46 g (67 %) of the title compound **7c** as a white solid, mp 151-152 °C (lit.⁶⁹ 151-155 °C). IR (ATR) cm⁻¹ 3284, 3197, 3053, 2960, 2969, 2929, 2852, 1644, 1499, 1446, 1309. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 5.06-4.88 (b, 1H), 4.72 (hept, *J* = 6.7 Hz, 1H), 3.30 (t, *J* = 5.6 Hz, 2H), 3.19 (t, *J* = 5.6 Hz, 2H), 1.97-1.89 (m, 2H), 1.13 (d, *J* = 6.8 Hz, 6H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 156.0, 43.9, 39.7, 37.7, 21.8, 19.2.

General Procedure for the reduction of 1-chlorodecane with SmI₂/ 4 ureate (Method A).

To an ice-cold mixture of the appropriate urea (2.28 mmol), THF (4.5 mL), and tetradecane (10.0 μL, 0.0384 mmol), was added 0.92 mL of a 2.5 M solution of *n*-BuLi in hexanes (2.3 mmol).

This mixture was stirred for 5 min, and 6.2 mL of a 0.092 M solution of SmI₂ in THF (0.57 mmol) were added, and allowed to stir for 5 min. 1-Chlorodecane (38 μ L, 0.19 mmol) was added and the mixture was allowed to stir. Aliquots were removed at 1 min and 1 h and immediately quenched with a 0.1 M *tert*-butanol in hexanes solution. The aliquot was mixed with 0.1 mL of 0.1 M HCl and 1 mL of Et₂O. The Et₂O extract from this mixture was analyzed by GC and GC-MS to obtain the yield of decane (identity of the product confirmed by comparison with authentic material).

1-Bromo-2-O-heptylbenzene (8a). DMF (2.9 mL) was added to 2-bromophenol (500 mg, 2.9 mmol). DBU (0.65 mL, 4.3 mmol) and 1-bromoheptane (0.65 mL, 4.3 mmol) were added. The mixture was stirred and heated to 60 °C in a pressure tube for 24 h. After cooling for 5 min water (10 mL) was added and the mixture was extracted with a 2:1 mixture of hexanes and Et₂O. (3 X 15 mL). The combined organic layers were washed with 10% NaOH (10 mL), water (10 mL), dried over Na₂SO₄, and concentrated under reduced pressure. Distillation (1.0 mm Hg, 175-180 °C) afforded 0.665 g (82%) of the title compound **8a** as a colorless oil. HRMS (EI) *m/z*: [M⁺] calcd for C₁₃H₁₉OBr 270.0625; found 270.0622. IR (ATR) cm⁻¹ 2926, 2856, 1587, 1482, 1291, 1276. ¹H NMR (300 MHz; CDCl₃ δ , ppm) 7.55 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.29-7.24 (m, 1H), 6.92-6.81 (m, 2H), 4.04 (t, *J* = 6.5 Hz, 2H), 1.91-1.84 (m, 2H), 1.55-1.50 (m, 2H), 1.42-1.31 (m, 6H), 0.92 (t, *J* = 6.7 Hz, 3H). ¹³C NMR (75 MHz; CDCl₃ δ , ppm) 155.5, 133.3, 128.4, 121.6, 113.2, 112.3, 69.1, 31.8, 29.1, 29.1, 26.0, 22.6, 14.1.

***N*-(4-Bromophenyl)-4-phenylbutanamide (8b).** Benzene (6.1 mL) was added to 4-phenylbutanoic acid (1.00 g, 0.00609 mol) and cooled in an ice-water bath. (COCl)₂ (0.94 mL, 0.011 mol) was added and the mixture was stirred for 3 h, then concentrated under reduced pressure. CH₂Cl₂ (2.1 mL) was added to the crude mixture which was stirred and cooled in an

ice-water bath. A solution of pyridine (3.0 mL), CH₂Cl₂ (1.0 mL) and 4-bromoaniline (1.25 g, 0.00731 mol) was slowly added. The mixture was warmed to room temperature and stirred overnight. Water (10 mL) and saturated NaHCO₃ (10 mL) was added and stirred for 30 min. The mixture was extracted with Et₂O (3 X 15 mL). The combined organic layers were washed with 10% NaOH (10 mL), water (10 mL), 10% HCl (10 mL), water (10 mL), then concentrated under reduced pressure. The residue was purified by column chromatography (SiO₂, gradient ranging from 2-10% EtOAc in hexanes) to provide 1.86 g of the title compound **8b** (95%) as a white powder, mp 119-120 °C. HRMS (EI) *m/z*: [M⁺] calcd for C₁₆H₁₆NOBr 317.0421; found 317.0412. IR (ATR) cm⁻¹ 3289, 3065, 3023, 2943, 2867, 1657, 1590, 1520, 1489 cm⁻¹. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 7.44-7.41 (m, 4H), 7.34-7.19 (m, 6H), 2.73 (t, *J* = 7.4 Hz, 2H), 2.36 (t, *J* = 7.2 Hz, 2H), 2.12-2.05 (m, 2H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 171.1, 141.2, 136.9, 132.0, 128.5, 128.5, 126.1, 121.4, 116.8, 36.7, 35.0, 26.7.

1-O-Ethyl-5-O-(4-chlorobutyl)-2,3-O-isopropylidene-β-D-ribofuranose (8d). Prepared in accordance with a previously reported procedure as a colorless oil.⁴⁵ ¹H NMR (300 MHz; CDCl₃ δ, ppm) 5.08 (s, 1H), 4.68 (d, *J* = 6.0 Hz, 1H), 4.60 (d, *J* = 6.0 Hz, 1H), 4.31 (t, *J* = 7.6 Hz, 1H), 3.75-3.69 (m, 1H), 3.58 (t, *J* = 3.4 Hz, 2H), 3.52-3.40 (m, 5H), 1.95-1.84 (m, 2H), 1.76-1.71 (m, 2H), 1.50 (s, 3H), 1.34 (s, 3H), 1.19 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 112.3, 107.8, 85.3, 85.0, 82.2, 71.8, 70.4, 62.9, 45.0, 29.4, 27.0, 26.5, 25.0, 14.9.

3-O-(4-Chlorobutyl)-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (8e). Prepared in accordance with a previously reported procedure as a colorless oil.⁷⁰ ¹H NMR (300 MHz; CDCl₃ δ, ppm) 5.88 (d, *J* = 3.6 Hz, 1H), 4.54 (d, *J* = 3.7 Hz, 1H), 4.30-4.26 (m, 1H), 4.12-4.07 (m, 2H), 4.01-3.96 (m, 1H), 3.87 (d, *J* = 3.0 Hz, 1H), 3.69-3.64 (m, 1H), 3.59-3.54 (m, 3H), 1.91-1.84 (m,

2H), 1.77-1.71 (m, 2H), 1.51 (s, 3H), 1.43 (s, 3H), 1.36 (s, 3H), 1.33 (s, 3H). ^{13}C NMR (75 MHz; CDCl_3 δ , ppm) 111.8, 109.0, 105.3, 82.5, 82.2, 81.2, 72.4, 69.6, 67.4, 44.8, 29.3, 27.0, 26.8, 26.8, 26.2, 25.4.

N-[2-(4-Chlorophenyl)ethyl]phenylpropanamide (**8f**). CH_2Cl_2 (3.0 mL) was added to hydrocinnamoyl chloride (0.44 mL, 0.0030 mol) and cooled in an ice-water bath with stirring. A solution of 2-(4-chlorophenyl)ethylamine (0.46 mL, 0.33 mol) in pyridine (0.29 mL, 0.0037 mol) and was added slowly. The mixture was allowed to warm to rt and stir overnight. Water (10 mL) and saturated NaHCO_3 (10 mL) was added and stirred for 10 min. The mixture was extracted with Et_2O (3 X 15 mL). The combined organic layers were washed with 10% NaOH (10 mL), water (10 mL), 10% HCl (10 mL), water (10 mL), then concentrated under reduced pressure. The residue was purified by recrystallization from a mixture of Et_2O in hexanes to provide 0.620 g (73%) of the title compound **8f** as a white powder, mp 116-117 °C. HRMS (EI) m/z : calcd for $\text{C}_{17}\text{H}_{18}\text{NOCl}$ 287.1071; found 287.1072. IR (ATR) cm^{-1} 3294, 3067, 3031, 2930, 2864, 1634, 1604, 1539, 1489, 1453. ^1H NMR (300 MHz; CDCl_3 δ , ppm) 7.30-7.18 (m, 7H), , 7.00 (d, J = 8.3 Hz, 2H), 5.49-5.42 (b, 1H), 3.48-3.41 (m, 2H), 2.96 (t, J = 7.5 Hz, 2H), 2.71 (t, J = 6.9 Hz, 2H), 2.44 (t, J = 7.5 Hz, 2H). ^{13}C NMR (75 MHz; CDCl_3 δ , ppm) 172.1, 140.8, 137.3, 132.3, 130.1, 128.7, 128.6, 128.4, 126.3, 40.5, 38.4, 35.0, 31.7.

1-Chloro-2-methyl-4-O-hexylbenzene (**8g**). DMF (6.6 mL) was added to 1-chloro-2-methyl-4-hydroxybenzene (1.00 g, 6.56 mmol). DBU (1.47 mL, 0.00986 mol) and 1-bromohexane (2.29 mL, 16.4 mmol) were added. The mixture was stirred and heated to 60 °C in a pressure tube for 24 h. After cooling for 5 min water (10 mL) was added and the mixture was extracted with a 2:1 mixture of hexanes and Et_2O . (3 X 15 mL). The combined organic layers were washed with 10% NaOH (10 mL), water (10 mL), dried over Na_2SO_4 , and concentrated under reduced

pressure. Distillation (0.6 mm Hg, 143-150 °C) afforded 1.21 g (81%) of the title compound **8g** as a colorless oil. HRMS (EI) m/z calcd for $C_{13}H_{19}OCl$ 226.1119; found 226.1123. IR (ATR) cm^{-1} 2929, 2859, 1596, 1576, 1482, 1470 cm^{-1} . 1H NMR (300 MHz; $CDCl_3$ δ , ppm) 7.24 (d, J = 8.8 Hz, 1H), 6.80 (d, J = 3.0 Hz, 1H), 6.60 (dd, J = 8.7, 3.0 Hz, 1H), 3.93 (t, J = 6.6 Hz, 2H), 2.36 (s, 3H), 1.83-1.74 (m, 2H), 1.50-1.35 (m, 8H), 0.96-0.92 (m, 3H). ^{13}C NMR (75 MHz; $CDCl_3$ δ , ppm) 157.7, 136.9, 129.5, 125.5, 117.1, 113.0, 68.2, 31.6, 29.2, 25.7, 22.6, 20.3, 14.1.

N,N-Dibutyl-4-chlorobenzene (**8h**). Prepared in accordance with a previously reported procedure as a colorless oil.⁷¹ 1H NMR (300 MHz; $CDCl_3$ δ , ppm) 7.16 (d, J = 9.2 Hz, 2H), 6.58 (d, J = 9.2 Hz, 2H), 3.29-3.24 (m, 4H), 1.63-1.53 (m, 4H), 1.44-1.32 (m, 4H), 0.99 (t, J = 7.3 Hz, 6H). ^{13}C NMR (75 MHz; $CDCl_3$ δ , ppm) 146.8, 128.9, 119.8, 112.8, 50.9, 29.3, 20.4, 14.0.

2-Fluoro-4-(2-phenylethyl)pyridine (**8i**). THF (7.0 mL) was added to (i-Pr)₂NH (755 μ L, 5.40 mmol) and the mixture was cooled to -84°C (EtOAc/ liquid N₂). *n*-BuLi (1.98 mL, 5.00 mmol) was added and the mixture was allowed to stir for 20 min. A solution of 2-fluoro-4-methylpyridine (500 mg, 4.50 mmol) in THF (2.0 mL) was added over 10 min. The mixture was allowed to warm to rt over 30 min then re-cooled to -84°C. Benzyl bromide (561 μ L, 5.72 mmol) was added and the mixture was allowed to warm to rt and stirred overnight. Water (15 mL) was added and the mixture was extracted with a 2:1 mixture of hexanes and Et₂O (3 X 15 mL). The combined organic layers were concentrated under reduced pressure. The residue was purified by column chromatography (SiO₂, 5% EtOAc in hexanes) to provide 723 mg (80%) of the title compound **8i** as a white solid, mp 64-66 °C. HRMS (EI) m/z : [M^+] calcd for $C_{13}H_{12}NF$ 201.0959; found 201.0958. IR (ATR) cm^{-1} 3063, 3030, 2929, 2863, 1607, 1554, 1454 cm^{-1} . 1H NMR (300 MHz; $CDCl_3$ δ , ppm) 8.11 (dd, J = 5.2, 0.6 Hz, 1H), 7.34-7.24 (m, 3H), 7.18-7.16 (m, 2H), 7.00-

6.98 (m, 1H), 6.73 (s, 1H), 2.97 (app. s, 4H). ^{13}C NMR (75 MHz; CDCl_3 δ , ppm) 163.4 (d, J = 238.2 Hz), 156.4 (d, J = 7.8 Hz), 147.2 (d, J = 15.3 Hz), 140.1, 128.5, 128.3, 126.3, 121.6 (d, J = 3.8 Hz), 109.1 (d, J = 36.7 Hz), 36.8 (d, J = 2.8 Hz), 36.2.

4-fluoro-1-[3-butoxyethoxy]propyl]benzene (8j). 3-(4-fluorophenyl)-propan-1-ol was prepared in accordance with a previously reported procedure as a colorless oil.³³ ^1H NMR (300 MHz; CDCl_3 δ , ppm) 7.19–7.14 (m, 2H), 7.01–6.95 (m, 2H), 3.67 (t, J = 6.4 Hz, 2H), 2.70 (t, J = 7.4 Hz, 2H), 1.90–1.83 (m, 2H), 1.81 (b, 1H). ^{13}C NMR (75 MHz; CDCl_3 δ , ppm) 161.2 (d, J = 243.2 Hz), 137.4 (d, J = 3.1 Hz), 129.7 (d, J = 7.7 Hz), 115.1 (d, J = 21.4 Hz), 61.9, 34.2 (d, J = 1.0 Hz), 31.1. Dichloromethane (4.7 mL) was added to 3-(4-fluorophenyl)-propan-1-ol (634 mg, 4.70 mmol) and butyl vinyl ether (720 μL , 5.6 mmol). The mixture was stirred and cooled in an ice-water bath. *p*-Toluenesulfonic acid (5 mg) was added and the mixture was kept at 0 °C and stirred for 30 min. Saturated $\text{NaHCO}_{3(\text{aq})}$ (3 mL) was added and the mixture was stirred for 5 min. The mixture was extracted with a 2:1 mixture of hexanes and Et_2O (3 X 10 mL). The combined organic layers were concentrated under reduced pressure. The residue was purified by column chromatography (SiO_2 , 3% EtOAc in hexanes) to provide 0.452 g (38%) of the title compound **8j** as a colorless oil. HRMS (EI) m/z : $[\text{M}^+]$ calcd for $\text{C}_{15}\text{H}_{22}\text{O}_2\text{F}$ 253.1598; found 253.1605. IR (ATR) cm^{-1} 2988, 2958, 2935, 2871, 1601, 1510, 1454, 1378 cm^{-1} . ^1H NMR (300 MHz; CDCl_3 δ , ppm) 7.18–7.14 (m, 2H), 7.00–6.95 (m, 2H), 4.69 (q, J = 5.3 Hz, 1H), 3.64–3.55 (m, 2H), 3.46–3.39 (m, 2H), 2.69 (t, J = 7.1 Hz, 2H), 1.93–1.84 (m, 2H), 1.61–1.52 (m, 2H), 1.42–1.37 (m, 2H), 1.33 (d, J = 5.3 Hz, 3H), 0.94 (t, J = 7.3 Hz, 3H). ^{13}C NMR (75 MHz; CDCl_3 δ , ppm) 161.1 (d, J = 243.1 Hz), 137.5 (d, J = 3.3 Hz), 129.7 (d, J = 7.9 Hz), 115.0 (d, J = 21.3 Hz), 99.8, 65.2, 64.2, 32.0, 31.7, 31.6 (d, J = 1.0 Hz), 31.6, 19.8, 19.4, 13.9.

4-Fluoro-1-O-decylbenzene (8k). DMF (4.5 mL) was added to 4-fluorophenol (1.00 g, 8.93 mmol). DBU (1.87 mL, 13.4 mmol) and 1-bromodecane (1.84 mL, 8.91 mmol) were added. The mixture was stirred and heated to reflux for 4 h. After cooling for 5 min water (10 mL) was added and the mixture was extracted with a 2:1 mixture of hexanes and Et₂O. (3 X 15 mL). The combined organic layers were washed with 10% NaOH (10 mL), water (10 mL), and concentrated under reduced pressure. The residue was purified by column chromatography (SiO₂, gradient ranging from hexanes to 1.5% EtOAc in hexanes) to provide 2.01 g (82%) of the title compound **8k** as a colorless oil. HRMS (EI) *m/z*: [M⁺] calcd for C₁₆H₂₅OF 252.1884; found 252.1883. IR (ATR) cm⁻¹ 2923, 2854, 1505, 1469 cm⁻¹. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 7.01-6.96 (m, 2H), 6.87-6.83 (m, 2H), 3.93 (t, *J* = 6.6 Hz, 2H), 1.81-1.74 (m, 2H), 1.50-1.31 (m, 14H), 0.92 (t, *J* = 6.4 Hz, 3H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 157.1 (d, *J* = 237.7 Hz), 155.2 (d, *J* = 2.2 Hz), 115.7 (d, *J* = 23.0 Hz), 115.4 (d, *J* = 7.7 Hz), 68.6, 31.9, 29.6, 29.5, 29.4, 29.3, 29.3, 26.0, 22.7, 14.1.

3β-Fluoro-5-cholestene (8l). Prepared in accordance with a previously reported procedure⁷² as a white solid, mp 94-96 °C (lit.⁷² mp 96 °C). ¹H NMR (300 MHz; CDCl₃ δ, ppm). 5.40-5.39 (m, 1H), 4.50-4.29 (m, 1H), 2.46-2.42 (m, 2H), 2.04-1.89 (m, 3H), 1.88-1.52 (m, 2H), 1.49-0.86 (m, 21H), 1.03 (s, 3H), 0.93 (d, *J* = 6.5 Hz, 3H), 0.88 (d, *J* = 1.2 Hz, 3H), 0.86 (d, *J* = 1.2 Hz, 3H), 0.68 (s, 3H) ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 139.3 (d, *J* = 12.6 Hz), 123.1 (d, *J* = 12.6 Hz), 92.9 (d, *J* = 173.9 Hz), 56.7, 56.1, 50.0, 42.3, 39.7, 39.5, 39.3, 36.5, 36.4 (d, *J* = 10.8 Hz), 35.8, 31.9, 31.9, 28.9, 28.7, 28.3, 28.0, 24.3, 23.8, 22.8, 22.6, 21.1, 19.3, 18.7, 11.9.

General procedure for the reduction of organohalides with 3.3 eq SmI₂/6.6 eq TEU/2 eq *t*-AmOH. To an ice-cold mixture of 271 mg TEU (1.88 mmol) and 1.5 mL of THF was added 0.75 mL of a 2.5 M solution of *n*-BuLi (1.9 mmol) in hexane. A solution of 0.00285 mol of the

organohalide compound in 1.0 mL of THF was added. This mixture was stirred for 5 min then 10.2 mL of a 0.092 M solution of SmI_2 (0.94 mmol) in THF was added followed rapidly by 62 μL of *t*-AmOH (0.57 mmol). The mixture was allowed to warm to rt and stirred overnight. Water (8 mL) was added and the mixture extracted with a 2:1 mixture of hexanes and Et_2O (5 X 5 mL). The concentrated mixture was purified by silica gel column chromatography as described below.

General procedure for the reduction of reduction of organohalides with 3.3 eq SmI_2 /13.2 eq TEU. To an ice-cold mixture of 542 mg TEU (3.76 mmol) and 1.0 mL of THF was added 1.50 mL of a 2.5 M solution of *n*-BuLi (3.8 mmol) in hexane. A solution of 0.285 mmol of the organohalide compound in 0.7 mL of THF was added. This mixture was stirred for 5 min then 10.2 mL of a 0.092 M solution of SmI_2 (0.94 mmol) in THF was added. The mixture was allowed to warm to rt and stirred overnight. Water (8 mL) was added and the mixture extracted with a 2:1 mixture of hexanes and Et_2O (5 X 5 mL). The concentrated mixture was purified by silica gel column chromatography as described below.

***O*-Heptylbenzene (9a).** (Table 5, Entry 1). The residue was purified by column chromatography (SiO_2 , gradient ranging from hexanes to 1% EtOAc in hexanes) to provide 50 mg (91%) of the title compound **9a** as a colorless oil. ^1H NMR (300 MHz; CDCl_3 δ , ppm). 7.35-7.30 (m, 2H), 6.97-6.93 (m, 3H), 3.99 (t, J = 6.6 Hz, 2H), 1.85-1.78 (m, 2H), 1.62-1.31 (m, 8H), 0.95 (t, J = 6.8 Hz, 3H). ^{13}C NMR (75 MHz; CDCl_3 δ , ppm) 159.2, 129.4, 120.5, 114.5, 67.9, 31.9, 29.4, 29.1, 26.1, 22.7, 14.2.⁷³

***N*-Phenyl-4-phenylbutanamide (9b).** (Table 5, Entry 2). The residue was purified by column chromatography (SiO_2 , gradient ranging from 2-10% EtOAc in hexanes) to provide 64 mg (94%)

of the title compound **9a** as a white powder, mp 94-96 °C (lit.⁷⁴ mp 95-96 °C). ¹H NMR (300 MHz; CDCl₃ δ, ppm) 7.54 (d, *J* = 3.8 Hz, 2H), 7.36-7.10 (m, 8H), 2.72 (t, *J* = 7.4 Hz, 2H), 2.37 (t, *J* = 7.2 Hz, 2H), 2.13-2.03 (m, 2H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 171.2, 141.3, 137.9, 128.9, 128.4, 128.4, 126.0, 124.2, 119.9, 36.7, 35.0, 26.8.⁷⁵

Cholest-5-ene (9c). (Table 5, Entry 3). The residue was purified by column chromatography (SiO₂, hexanes) to provide 84 mg (80%) of the title compound **9c** as a white powder. mp 93-94 °C (lit.⁷⁶ mp 95 °C). ¹H NMR (300 MHz; CDCl₃ δ, ppm) 5.30–5.28 (m, 1H), 2.34–2.19 (m, 1H), 2.07-1.92 (m, 3H), 1.92-1.69 (m, 3H), 1.69-1.32 (m, 12H), 1.32-0.79 (m, 11H), 1.02 (s, 3H), 0.92 (d, *J* = 6.4 Hz, 3H), 0.90 (d, *J* = 1.3 Hz, 3H), 0.88 (d, *J* = 1.3 Hz, 3H), 0.70 (s, 3H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 143.7, 119.0, 56.9, 56.2, 50.6, 42.3, 39.9, 39.9, 39.6, 37.5, 36.2, 35.8, 32.9, 31.9, 31.9, 28.3, 28.1, 28.0, 24.3, 23.9, 22.9, 22.6, 20.8, 19.5, 18.7, 11.9.⁷⁷

1-O-Ethyl-5-O-butyl-2,3-O-isopropylidene-β-D-ribofuranose (9d). (Table 5, Entry 4). The residue was purified by column chromatography (SiO₂, gradient ranging from 1-3% EtOAc in hexanes) to provide 68 mg (87%) of the title compound **9d** as a colorless oil. ¹H NMR (300 MHz; CDCl₃ δ, ppm). 5.07 (s, 1H), 4.67 (d, *J* = 6.5 Hz, 1H), 4.59 (d, *J* = 6.9 Hz, 1H), 4.30 (t, *J* = 6.9 Hz, 1H), 3.77-3.66 (m, 1H), 3.50-3.38 (m, 5H), 1.59-1.48 (m, 2H), 1.48 (s, 3H), 1.43 – 1.31 (m, 2H), 1.31 (s, 3H), 1.16 (t, *J* = 7.1 Hz, 3H), 0.91 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 112.2, 107.7, 85.3, 85.0, 82.3, 71.7, 71.2, 62.8, 31.7, 26.4, 25.0, 19.3, 14.9, 13.9.⁴⁵

3-O-Butyl-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (9e). (Table 5, Entry 5). The residue was purified by column chromatography (SiO₂, gradient ranging from 3-6% EtOAc in hexanes) to provide 66 mg (74%) of the title compound **9e** as a colorless oil. ¹H NMR (300

MHz; CDCl₃ δ, ppm) 5.89 (d, *J* = 3.7 Hz, 1H), 4.54 (d, *J* = 3.7 Hz, 1H), 4.35-4.28 (m, 1H), 4.15-4.06 (m, 2H), 4.01-3.96 (m, 1H), 3.86 (d, *J* = 3.1 Hz, 1H), 3.65-3.48 (m, 2H), 1.57-1.52 (m, 2H), 1.50 (s, 3H), 1.44-1.34 (m, 2 H), 1.43 (s, 3H), 1.35 (s, 3H), 1.32 (s, 3H), 0.92 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 111.6, 108.7, 105.2, 82.4, 82.0, 81.1, 72.4, 70.3, 67.1, 31.7, 26.7, 26.7, 26.1, 25.3, 19.1, 13.7.⁷⁸

***N*-(2-Phenyl)ethyl-3-phenylpropanamide (9f).** (Table 5, Entry 6). The residue was purified by column chromatography (SiO₂, gradient ranging from 5-20% EtOAc in hexanes) to provide 62 mg (74%) of the title compound **9f** as a white solid, mp 95-96 °C (lit.⁷⁹ mp 96-97 °C) ¹H NMR (300 MHz; CDCl₃ δ, ppm) 7.33-7.19 (m, 8H), 7.11 (d, *J* = 7.0 Hz, 2H), 5.48-5.28 (b, 1H), 3.53-3.47 (m, 2H), 2.99-2.94 (m, 2H), 2.76 (t, *J* = 6.9 Hz, 2H), 2.47-2.42 (m, 2H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 172.0, 140.8, 138.8, 128.7, 128.6, 128.5, 128.3, 126.4, 126.2, 40.5, 38.5, 35.6, 31.7.⁷⁹

1-O-Hexyl-2-methylbenzene (9g). (Table 6, Entry 6). To an ice-cold mixture of 648 mg BI (4.56 mmol) and 1.5 mL of THF was added 1.80 mL of a 2.5 M solution of *n*-BuLi (4.6 mmol) in hexane. A solution of 65 mg (0.29 mmol) of **8g** in 1.0 mL of THF was added. This mixture was stirred for 5 min then 12.4 mL of a 0.092 M solution of SmI₂ (1.1 mmol) in THF was added. The mixture was allowed to warm to rt and stirred overnight. Water (8 mL) was added and the mixture extracted with a 2:1 mixture of hexanes and Et₂O (5 X 5mL). The concentrated mixture was purified by column chromatography (SiO₂, hexanes) to provide 42 mg (77%) of the title compound **9g** as a colorless oil. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 7.23-7.18 (m, 1H), 6.81-6.74 (m, 3H), 3.98 (t, *J* = 6.6 Hz, 2H), 2.37 (s, 3H), 1.84-1.77 (m, 2H), 1.53-1.36 (m, 6H), 0.98-

0.93 (m, 3H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 159.2, 139.4, 129.2, 121.3, 115.4, 111.4, 67.8, 31.7, 29.3, 25.8, 22.7, 21.6, 14.1.⁸⁰

N,N-Dibutylbenzene (**9h**). (Table 6, Entry 10). To an ice-cold mixture of 648 mg PPU (4.56 mmol) and 1.5 mL of THF was added 1.80 mL of a 2.5 M solution of *n*-BuLi (4.6 mmol) in hexane. A solution of 68 mg (0.29 mmol) of **8h** in 1.0 mL of THF was added. This mixture was stirred for 5 min then 12.4 mL of a 0.092 M solution of SmI₂ (1.1 mmol) in THF was added. The mixture was allowed to warm to rt and stirred overnight. Water (8 mL) was added and the mixture extracted with a 2:1 mixture of hexanes and Et₂O (5 X 5mL). The concentrated mixture was purified by column chromatography (SiO₂, hexanes) to provide 49 mg (83%) of the title compound **9h** as a colorless oil. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 7.25-7.19 (m, 2H), 6.67-6.61 (m, 3H), 3.30-3.25 (m, 4H), 1.63-1.53 (m, 4H), 1.43-1.31 (m, 4H), 0.97 (t, *J* = 7.3 Hz, 6H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 148.1, 129.1, 115.0, 111.6, 50.7, 29.4, 20.3, 14.0.⁸¹

4-(2-Phenylethyl)pyridine (**9i**). (Table 5, Entry 11). The residue was purified by column chromatography (SiO₂, gradient ranging from 5-15% EtOAc in hexanes) to provide 38 mg (73%) of the title compound **9i** as a white solid, mp 69-70 °C. (lit.⁸² mp 69 °C) ¹H NMR (300 MHz; CDCl₃ δ, ppm) 8.51, (d, *J* = 5.8 Hz, 2H), 7.31-7.09 (m, 7H), 2.95 (app. s, 4H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 150.5, 149.7, 140.7, 128.5, 128.4, 126.3, 123.9, 37.1, 36.6.⁸³

[3-Butoxyethoxy)propyl]benzene (**9j**). (Table 6, Entry 12). To an ice-cold mixture of 648 mg PPU (4.56 mmol) and 1.5 mL of THF was added 1.80 mL of a 2.5 M solution of *n*-BuLi (4.6 mmol) in hexane. A solution of 72 mg (0.29) mmol of **8j** in 1.0 mL of THF was added. This mixture was stirred for 5 min then 12.4 mL of a 0.092 M solution of SmI₂ (1.1 mmol) in THF was added. The mixture was allowed to warm to rt and stirred overnight. Water (8 mL) was

added and the mixture extracted with a 2:1 mixture of hexanes and Et₂O (5 X 5mL). The concentrated mixture was purified by column chromatography (SiO₂, gradient ranging from hexanes to 1% EtOAc in hexanes) to provide 57 mg (85%) of the title compound **9j** as a colorless oil. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 7.33-7.21 (m, 5H), 4.70 (q, *J* = 5.3 Hz, 1H), 3.65-3.57 (m, 2H), 3.49-3.40 (m, 2H), 2.75-2.70 (m, 2H), 1.97-1.88 (m, 2H), 1.60-1.53 (m, 2H), 1.43-1.32 (m, 2H), 1.34 (d, *J* = 5.4 Hz, 3H), 0.94 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 142.0, 128.5, 128.3, 125.8, 99.8, 65.2, 64.5, 32.5, 32.0, 31.5, 19.9, 19.5, 13.9.⁸⁴

O-Decylbenzene (9k). (Table 6, Entry 13). To an ice-cold mixture of 648 mg PPU (4.56 mmol) and 1.4 mL of THF was added 1.8 mL of a 2.5 M solution of *n*-BuLi (4.5 mmol) in hexane. A solution of 72 mg (0.29 mmol) of **8k** in 1.5 mL of THF was added. This mixture was stirred for 5 min then 12.4 mL of a 0.092 M solution of SmI₂ (1.1 mmol) in THF was added. The mixture was allowed to warm to rt and stirred overnight. Water (10 mL) was added and the mixture extracted with a 2:1 mixture of hexanes and Et₂O (5 X 5mL). The concentrated mixture was purified by column chromatography (SiO₂, gradient ranging from hexanes to 1% EtOAc in hexanes) to provide 50 mg (74%) of the title compound **9k** as a colorless oil. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 7.34-7.29 (m, 2H), 6.99-6.92 (m, 3H), 3.99 (t, *J* = 6.6 Hz, 2H), 1.87-1.77 (m, 2H), 1.52-1.32 (m, 14H), 0.95-0.90 (m, 3H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 159.2, 129.4, 120.5, 114.5, 67.9, 31.9, 29.6, 29.6, 29.5, 29.4, 29.3, 26.1, 22.7, 14.2.⁸⁵

1-(4-Chloro)butoxy-4-chloronaphthalene (10). DMF (5.5 mL) was added to 4-chloro-1-naphthol (1.31 g, 0.00734 mol). DBU (1.97 mL, 0.0132 mol) was added and the mixture was cooled with stirring to 0 °C. 1-Bromo-4-chlorobutane (1.45 mL, 0.0132 mol) were added, and the mixture was allowed to warm slowly to rt and stir for 24 h, then heated to 45 °C for an additional 24 h. Water (10 mL) was added and the mixture was extracted with a 2:1 mixture of

hexanes and Et₂O (3 X 10 mL). The combined organic layers were concentrated under reduced pressure and purified by column chromatography (SiO₂, gradient ranging from hexanes to 2% EtOAc in hexanes) to provide 1.42 g (72%) of the title compound **10** as a colorless oil. HRMS (EI) *m/z*: [M⁺] calcd for C₁₄H₁₄OC₂ 268.0416; found 268.01414. IR (ATR) cm⁻¹ 3071, 2955, 2873, 1621, 1588, 1456, 1424, 1374. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 8.32 (dd, *J* = 8.3, 1.2 Hz, 1H), 8.24 (dd, *J* = 9.0, 1.2 Hz, 1H), 7.68-7.54 (m 2H), 7.47 (d, *J* = 8.2 Hz, 1H), 6.70 (d, *J* = 8.3 Hz, 1H), 4.17-4.13 (m, 2H), 3.72-3.68 (m, 2H), 2.13-2.09 (m, 4H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 153.7, 131.3, 127.5, 126.6, 126.0, 125.8, 124.3, 123.2, 122.4, 104.6, 67.4, 44.8, 29.5, 26.6.

General procedure for the reduction of reduction of 1-(4-chloro)butoxy-4-

chloronaphthalene (10), Table 7. To an ice-cold mixture of the appropriate activator, 1.0 mL of THF and *n*-BuLi in hexanes (if required) were added. This mixture was cooled to -98 °C (CH₃OH/liquid N₂), stirred for 5 min, and a solution of 77 mg (0.29 mmol) of dichloride **10** in 0.7 mL of THF was added. This mixture was stirred for 5 min then 9.3 mL of a 0.092 M solution of SmI₂ (0.86 mmol) in THF was added, followed rapidly by 62 μL of *t*-AmOH (0.57 mmol). The mixture was allowed to warm to rt and stirred overnight. Water (8 mL) was added and the mixture extracted with a 2:1 mixture of hexanes and Et₂O (5 X 5mL). The concentrated mixture was purified by column chromatography (SiO₂, gradient ranging from hexanes to 1% EtOAc in hexanes affording products **11** through **13**.

1-(4-Chlorobutoxy)naphthalene (11). White solid, mp 41-42 °C. HRMS (EI) *m/z*: [M⁺] calcd for C₁₄H₁₅OCl 234.0817; found 234.0812. IR (ATR) cm⁻¹ 3052, 2950, 2875, 1595, 1574, 1390. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 8.31-8.28 (m, 1H), 7.85-7.82 (m, 1H), 7.54-7.37 (m, 4H), 6.83 (d, *J* = 7.6 Hz, 1H), 4.23-4.19 (m, 2H), 3.73-3.70 (m, 2H), 2.15-2.11 (m, 4H). ¹³C NMR (75

MHz; CDCl₃ δ, ppm) 154.5, 134.4, 127.4, 126.4, 125.8, 125.6, 125.1, 121.9, 120.2, 104.4, 67.0, 44.8, 29.5, 26.6.

1-Butoxy-4-chloronaphthalene (12). Colorless oil. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 8.37 (dd, *J* = 8.3, 0.6 Hz, 1H), 8.26 (d, *J* = 8.4, 0.6 Hz, 1H), 7.68-7.55 (m, 2H), 7.48 (d, *J* = 8.3 Hz, 1H), 6.72 (dd, *J* = 8.3 Hz, 1H), 4.13 (t, *J* = 6.3 Hz, 2H), 1.99-1.90 (m, 2H), 1.70-1.58 (m, 2H), 1.08 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 154.0, 131.3, 127.4, 126.7, 125.8, 125.8, 124.1, 122.8, 122.5, 104.5, 68.0, 31.3, 19.4, 13.9.⁴⁵

1-Butoxynaphthalene (13). Colorless oil. ¹H NMR (300 MHz; CDCl₃ δ, ppm) 8.23-8.19 (m, 1H), 7.71-7.68 (m, 1H), 7.40-7.24 (m, 4H), 6.70 (dd, *J* = 7.1, 1.4 Hz), 4.04 (t, *J* = 6.4 Hz, 2H), 1.85-1.79 (m, 2H), 1.55-1.48 (m, 2H), 0.94 (t, *J* = 7.4 Hz, 2H). ¹³C NMR (75 MHz; CDCl₃ δ, ppm) 154.9, 134.5, 127.4, 126.3, 125.9, 125.7, 125.0, 122.1, 119.9, 104.5, 67.8, 31.4, 19.5, 13.9.⁸⁶

General procedure for the determination of effective redox potential of SmI₂/2 TEU^{•-} and

SmI₂/4 TEU^{•-}. To an ice-cold mixture of TEU (either 173 mg, 0.120 mmol, or 346 mg, 0.240 mmol), THF (6.0 mL), and tetradecane (10.0 μL, 0.0384 mmol), was added either 0.48 or 0.96 mL of a 2.5 M solution of *n*-BuLi in hexanes (either 0.12 or 0.24 mmol). This mixture was stirred for 5 min, and 6.5 mL of a 0.092 M solution of SmI₂ in THF (0.60 mmol), and allowed to stir for 5 min. The substrate (0.20 mmol) was added and the mixture was allowed to stir for 15 min. An aliquot was removed and immediately quenched with a 0.1 M *tert*-butanol in hexanes solution. The aliquot was mixed with 0.1 mL of 0.1 M HCl and 1 mL of Et₂O. The Et₂O extract was analyzed by GC and GC-MS to obtain the yield of reduced product (identity of the product confirmed by comparison with authentic material).

Visible spectrum of 1:1 SmI₂/TEU⁻. THF (15.9 mL) was added to a flask equipped with the UV-vis probe and 26 mg TEU (0.18 mmol) and a background was taken. This mixture was cooled in an ice-water bath and 0.072 mL of a 2.5 M solution of *n*-BuLi (0.18 mmol) in hexane was added. This mixture was stirred for 5 min, warmed to rt, then 2.0 mL of a 0.092 M solution of SmI₂ in THF (0.18 mmol) was added. After stirring for 1 min, the spectrum was acquired.

Visible spectrum of 1:2 SmI₂/TEU⁻. THF (15.9 mL) was added to a flask equipped with the UV-vis probe and 52 mg TEU (0.36 mmol) and a background was taken. This mixture was cooled in an ice-water bath and 0.14 mL of a 2.5 M solution of *n*-BuLi (0.36 mmol) in hexane was added. This mixture was stirred for 5 min, warmed to rt, then 2.0 mL of a 0.092 M solution of SmI₂ in THF (0.18 mmol) was added. After stirring for 1 min, the spectrum was acquired.

Visible spectrum of 1:3 SmI₂/TEU⁻. THF (15.8 mL) was added to a flask equipped with the UV-vis probe and 78 mg TEU (0.54 mmol) and a background was taken. This mixture was cooled in an ice-water bath and 0.22 mL of a 2.5 M solution of *n*-BuLi (0.54 mmol) in hexane was added. This mixture was stirred for 5 min, warmed to rt, then 2.0 mL of a 0.092 M solution of SmI₂ in THF (0.18 mmol) was added. After stirring for 1 min, the spectrum was acquired.

Visible spectrum of 1:4 SmI₂/TEU⁻. THF (15.7 mL) was added to a flask equipped with the UV-vis probe and 104 mg TEU (0.72 mmol) and a background was taken. This mixture was cooled in an ice-water bath and 0.29 mL of a 2.5 M solution of *n*-BuLi (0.72 mmol) in hexane was added. This mixture was stirred for 5 min, warmed to rt, then 2.0 mL of a 0.092 M solution of SmI₂ in THF (0.18 mmol) was added. After stirring for 1 min, the spectrum was acquired.

ASSOCIATED CONTENT

¹H and ¹³C NMR of all title compounds. This material is free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*E-mail: mcdonald@lycoming.edu. Tel: 570-321-4186.

Present Addresses

[†](C.C.M.) University of Michigan, Department of Chemistry, Williard Henry Dow Laboratory, 930 North University Ave., Ann Arbor MI 48109 US.

^{††}(J.R.M.) Rowan University, Department of Chemical Engineering, South Jersey Technology Park, 107 Gilbreth Parkway, Mantua Township, NJ, 08062 US.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGEMENTS

Acknowledgement is made to the donors of the American Chemical Society Petroleum Research Fund for support of this research (grant # 52067-UR1). We thank the Joanne and Arthur Haberberger Fellowship program at Lycoming College for support of C.C.M.. C.E.M. thanks Lycoming College for a professional development grant and sabbatical in support of this work. High resolution mass spectrometry was performed at the University of Buffalo. The authors are also indebted to Holly Bendorf and David Sampsell for helpful discussions.

REFERENCES

1. Szostak, M.; Fazakerley, N. J.; Parmar, D.; Procter, D. J. *Chem. Rev.* **2014**, *114*, 5959-6039.
2. Inanaga, J.; Ishikawa, M.; Yamaguchi, M. *Chem. Lett.* **1987**, 1485-1486.
3. Shotwell, J. B.; Sealy, J. M.; Flowers, R. A., II *J. Org. Chem.* **1999**, *64*, 5251-5255.
4. Enemærke, R. J.; Hertz, T.; Skrystrup, T.; Daasbjerg, K. *Chem. Eur. J.* **2000**, *6*, 3747-3754.

5. Procter, D. J.; Flowers, R. A., II, Skrydstrup, T. *Organic Synthesis Using Samarium Diodide: A Practical Guide*; Royal Society of Chemistry: Cambridge, UK, 2010.
6. Sarraf, A. M.; Krahn, D. F.; Donovan, S. M.; O'Neil, R. M. *Mutat. Res.* **1997**, *380*, 167-177.
7. Kimbrough, R. D.; Gaines, T. B. *Bull. Environ. Contam. Toxicol.* **1973**, *10*, 225-226.
8. Lee, K. P.; Trochimowicz, H. J. *J. Natl. Cancer Inst.* **1982**, *68*, 157-171.
9. Jackson, H.; Jones, A. R.; Cooper, E. R. A. *J. Reprod. Fert.* **1969**, *20*, 263-269.
10. Zijlstra, J. A.; Brussee, J.; van der Gen, A.; Vogel, E. W. *Mutat. Res.* **1989**, *212*, 193-211.
11. Ankner, T.; Fridén-Saxin, M.; Permberton, N.; Seifert, T.; Grøtil, M.; Luthman, K.; Hilmersson, G. *Org. Lett.* **2010**, *12*, 2210-2213.
12. Berndt, M.; Hölemann, A.; Niermann, A.; Bentz, C.; Zimmer, R.; Reissig, H.-U. *Eur. J. Org. Chem.* **2012**, 1299-1302.
13. Machrouhi, F.; Hamann, B.; Namy, J.-L.; Kagan, H. B. *Synlett* **1996**, 633-634.
14. Machrouhi, F.; Namy, J.-L. *Tetrahedron Lett.* **1999**, *40*, 1315-1318.
15. Miquel, N.; Doisneau, G.; Beau, J.-M. *Angew. Chem. Int. Ed.* **2000**, *39*, 4111-4114.
16. Machrouhi, F.; Namy, J.L.; Kagan, H.B. *Tetrahedron Lett.* **1997**, *38*, 7183-7186.
17. McDonald, C. E.; Galka, A. M.; Green, A. I.; Keane, J. M.; Kowalchick, J.; Micklitsch, C. M.; Wisnoski, D. D. *Tetrahedron Lett.* **2001**, *42*, 163-166.
18. Huang, P.-Q.; Lang, Q.-W.; Wang, A.-E.; Zheng, J.-F. *Chem. Commun.* **2015**, *51*, 1096-1099.
19. Choquette, K. A.; Sadasivam, D. V.; Flowers, R. A. II *J. Am. Chem. Soc.* **2011**, *133*, 10655-10661.
20. Hasegawa, E.; Curran, D. P. *J. Org. Chem.* **1993**, *58*, 5008-5010.
21. Just-Baringo, X.; Procter, D. J. *Acc. Chem. Res.* **2015**, *48*, 1263-1275.
22. Kamochi, Y.; Kudo, T. *Tetrahedron* **1992**, *48*, 4301-4312.
23. Jensen, C. M.; Lindsay, K. B.; Taaning, R. H.; Karaffa, J.; Hansen, A. M.; Skrydstrup, T. *J. Am. Chem. Soc.* **2005**, *127*, 6544-6545.
24. Parmar, D.; Duffy, L. A.; Sadasivam, D. V.; Matsubara, H.; Bradley, P. A.; Flowers, R. A. II; Procter, D. J. *J. Am. Chem. Soc.* **2009**, *131*, 15467-15473.
25. Collins, K. D.; Oliveira, J. M.; Guazzelli, G.; Sautier, B.; De Grazia, S.; Matsubara, H.; Helliwell, M.; Procter, D. J. *Chem. Eur. J.* **2010**, *16*, 10240-10249.
26. Szostak, M.; Sautier, B.; Spain, M.; Behlendorf, M.; Procter, D. J. *Angew. Chem. Int. Ed.* **2013**, *52*, 12559-12563.
27. Flowers, R. A., II *Synlett* **2008**, 1427-1439.
28. Szostak, M.; Spain, M.; Parmar, D.; Procter, D. J. *Chem. Commun.* **2012**, *48*, 330-346.
29. Dahlén, A.; Hilmersson, G.; Knettle, B. W.; Flowers, R. A., II *J. Org. Chem.* **2003**, *68*, 4870-4875.
30. Dahlén, A.; Hilmersson, G. *Tetrahedron Lett.* **2003**, *44*, 2661-2664.
31. Dahlén, A.; Hilmersson, G. *Chem. Eur. J.* **2003**, *9*, 1123-1128.
32. Szostak, M.; Spain, M.; Procter, D. J. *Chem. Commun.* **2011**, *47*, 10254-10256.
33. Szostak, M.; Spain, M.; Procter, D. J. *Org. Lett.* **2012**, *14*, 840-843.
34. Szostak, M.; Spain, M.; Eberhart, A. J.; Procter, D. J. *J. Am. Chem. Soc.* **2014**, *136*, 2268-2271.
35. Maity, S.; Hoz, S. *Chem. Eur. J.* **2015**, *21*, 18394-18400.
36. Cabri, W.; Candiani, I.; Colombo, M.; Franzoi, L.; Bedeschi, A. *Tetrahedron Lett.* **1995**, *36*, 949-952.

37. Kumaran, R.; Brüdgam, I.; Reissig, H.-U. *Synlett* **2008**, 991-994.
38. Janjetovic, M.; Träff, A. M.; Ankner, T.; Wettergren, J.; Hilmersson, G. *Chem Commun.* **2013**, 49, 1826-1828.
39. Keck, G. E.; Savin, K. A.; Weglarz, M. A. *J. Org. Chem.* **1995**, 60, 3194-3204.
40. Masayoshi, N.; Katagiri, K.; Imamoto, T. *Bull. Chem. Soc. Jpn.* **2001**, 74, 1417-1424.
41. McDonald, C. E.; Ramsey, J. D.; Grant, J. A.; Howerter, K. A. *Tetrahedron Lett.* **2009**, 50, 5308-5310.
42. McDonald, C. E.; Ramsey, J. D.; Sampsell, D. G.; Butler, J. A.; Cecchini, M. R. *Org. Lett.* **2010**, 12, 5178-5181.
43. Hall, H. K. *J. Am. Chem. Soc.* **1957**, 79, 5441-5444.
44. Ozari, Y.; Jagur-Grodzinski, J. *J. C. S. Chem. Comm.* **1974**, 295-296.
45. McDonald, C. E.; Ramsey, J. D.; Sampsell, D. G.; Anderson, L. A.; Krebs, J. E.; Smith, S. N. *Tetrahedron* **2013**, 69, 2947-2953.
46. Harkness, M. B.; Alvarado, E.; Badaj, A. C.; Skrela, B. C.; Fan, L.; Lavoie, G. G. *Organometallics* **2013**, 32, 3309-3321.
47. Lucas, R. L.; Powell, D. R.; Borovik, A. S. *J. Am. Chem. Soc.* **2005**, 127, 11596-11597.
48. Leitch, D. C.; Schafer, L. L. *Organometallics* **2010**, 29, 5162-5172.
49. Srinivas, P.; Srinivas, K.; Likhari, P. R.; Sridhar, B.; Mohan, K. V.; Bhargava, S.; Kantam, M. L. *J. Organomet. Chem.* **2011**, 696, 795-801.
50. Pothiraja, R.; Milanov, A. P.; Barreca, D.; Gasparatto, A.; Becker, H.-W.; Winter, M.; Fischer, R. A.; Devi, A. *Chem. Commun.* **2009**, 1978-1980.
51. Atagi, L. M.; Mayer, J. M. *Organometallics* **1994**, 13, 4794-4803.
52. Jilek, R. E.; Tomson, N. C.; Scott, B. L.; Boncella, J. B. *Inorg. Chim. Acta* **2014**, 422, 78-85.
53. Leitch, D. C.; Payne, P. R.; Dunbar, C. R.; Schafer, L. L. *J. Am. Chem. Soc.* **2009**, 131, 18246-18247.
54. Jiao, L.-Y.; Oestreich, M. *Org. Lett.* **2013**, 15, 5374-5377.
55. Sham, H. L.; Betebenner, D. A.; Rosenbrook, W.; Herrin, T.; Saldivar, A.; Vasavanonda, S.; Plattner, J. J.; Norbeck, D. W. *Bioorg. Med. Chem. Lett.* **2004**, 14, 2643-2645.
56. Fuh, M.-R.S.; Lin, T.-Y.; Chang, S.-C. *Talanta*, **1998**, 46, 861-866.
57. Dahlén, A.; Hilmersson, G. *Tetrahedron Lett.* **2002**, 43, 7197-7200.
58. Dahlén, A.; Nilsson, Å.; Hilmersson, G. *J. Org. Chem.* **2006**, 71, 1576-1580.
59. Curran, D. P.; Totleben, M. J. *J. Am. Chem. Soc.* **1992**, 114, 6050-6058.
60. Szostak, M.; Spain, M.; Procter, D. J. *J. Org. Chem.* **2014**, 79, 2522-2537.
61. Choquette, K. A.; Sadasivam, D., V.; Flowers, R. A. II *J. Am. Chem. Soc.* **2010**, 132, 17396-17398.
62. Leitch, D. C.; Beard, J. D.; Thomson, R. K.; Wright, V. A.; Patrick, B. O.; Schafer, L. L. *Eur. J. Inorg. Chem.* **2009**, 2691-2701.
63. Curran, D. P.; Gu, X.; Zhang, W.; Dowd, P. *Tetrahedron* **1997**, 53, 9023-9042.
64. Nowick, J. S.; Keith, M. A.; Bellamo, K. A.; Love, J. A.; Martinez, E. J.; Noronha, G.; Smith, E. M.; Ziller, J. W. *J. Am. Chem. Soc.* **1995**, 117, 88-99.
65. Kogon, I. C. *J. Am. Chem. Soc.* **1957**, 79, 2253-2254.
66. Mido, Y.; Gohda, T. *Bull. Chem. Soc. Jpn.* **1975**, 48, 2704-2707.
67. Uribe, L. T. M.; Pindter, C. M. O.; Mido, T. S. Y. *Rev. Soc. Quim. Mex.* **1978**, 22, 433-5.
68. Aelony, D.; McKillop, W. J.; *J. Heterocycl. Chem.* **1972**, 9, 687-690.
69. Dyer, E.; Scott, H. *J. Am. Chem. Soc.* **1957**, 79, 672-675.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
70. Moeker, J.; Thiem, J. *Eur. J. Org. Chem.* **2008**, 28, 4842-4847.
71. Watanabe, Y.; Tsuji, Y.; Ige, H.; Ohsugi, Y.; Ohta, T. *J. Org. Chem.* **1984**, 49, 3359-3363.
72. Rozen, S.; Faust, Y.; Ben-Yakov, H. *Tetrahedron Lett.* **1979**, 20, 1823-1826.
73. Cano, R.; Ramon, D. J.; Yus, M. *J. Org. Chem.* **2011**, 76, 654-660.
74. Fear, E. J. P.; Thrower, J.; Veitch, J. *J. Appl. Chem.* **1955**, 5, 589-594.
75. Ishihara, K.; Ohara, S.; Yamamoto, H. *J. Org. Chem.* **1996**, 61, 4196-4197.
76. Ledger, R.; *Tetrahedron* **1964**, 20, 2413-2421.
77. Pan, X.; Lacôte, E.; Lalev'ee, J.; Curran, D. P. *J. Am. Chem. Soc.* **2012**, 134, 5669-5674.
78. Krueger, E.; Hopkins, T.; Keaney, M.; Walters, M.; Boldi, A. *J. Comb. Chem.* **2002**, 4, 229-238.
79. Sheikh, M. C.; Takagi, S.; Yoshimura, T.; Morita, H. *Tetrahedron* **2010**, 66, 7272-7278.
80. Sutter, M.; Lafon, R.; Raoul, Y.; Metay, E.; Lemaire, M. *Eur. J. Org. Chem.* **2013**, 26, 5902-5916.
81. Beller, M.; Breindl, C.; Riermeier, T. H.; Tillack, A. *J. Org. Chem.* **2001**, 66, 1403-1412.
82. Schmaunz, C. E.; Pabel, J.; Wanner, K. T. *Synthesis* **2010**, 13, 2147-2160.
83. Lautens, M.; Roy, A.; Fukuoka, K.; Fagnou, K.; Martin-Matute, B. *J. Am. Chem. Soc.* **2001**, 123, 5358-5359.
84. Kulibekov, M. R. *Azerb. Khim. Zh.* **1964**, 63-68.
85. Juršić, B. *Tetrahedron* **1988**, 44, 6677-6680.
86. Gowrisankar, S.; Sergeev, A. G.; Anbarasan, P.; Spannenberg, A.; Neumann, H.; Beller, M. *J. Am. Chem. Soc.* **2010**, 132, 11592-11598.